Short Interest in Enliven Therapeutics, Inc. (NASDAQ:ELVN) Rises By 10.3%

Enliven Therapeutics, Inc. (NASDAQ:ELVN) saw a large growth in short interest during the month of September. As of September 30th, there was short interest totalling 6,100,000 shares, a growth of 10.3% from the September 15th total of 5,530,000 shares. Approximately 21.1% of the company’s stock are short sold. Based on an average daily volume of 241,600 shares, the short-interest ratio is currently 25.2 days.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $37.00 target price on shares of Enliven Therapeutics in a research report on Tuesday, October 1st.

Enliven Therapeutics Stock Performance

Shares of NASDAQ:ELVN traded down $0.10 during trading hours on Thursday, hitting $28.02. 115,367 shares of the company’s stock traded hands, compared to its average volume of 261,112. The company’s fifty day simple moving average is $23.80 and its two-hundred day simple moving average is $22.54. The company has a market cap of $1.32 billion, a price-to-earnings ratio of -14.52 and a beta of 1.10. Enliven Therapeutics has a 52 week low of $9.80 and a 52 week high of $28.62.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.17. On average, analysts anticipate that Enliven Therapeutics will post -1.98 EPS for the current fiscal year.

Insider Transactions at Enliven Therapeutics

In other Enliven Therapeutics news, Director Richard A. Heyman sold 1,270 shares of the stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $27.67, for a total transaction of $35,140.90. Following the transaction, the director now owns 124,490 shares of the company’s stock, valued at $3,444,638.30. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, Director Richard A. Heyman sold 1,270 shares of Enliven Therapeutics stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $27.67, for a total value of $35,140.90. Following the completion of the transaction, the director now directly owns 124,490 shares of the company’s stock, valued at approximately $3,444,638.30. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Benjamin Hohl sold 991 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $27.53, for a total value of $27,282.23. The disclosure for this sale can be found here. In the last 90 days, insiders sold 180,409 shares of company stock valued at $4,800,526. Insiders own 29.20% of the company’s stock.

Institutional Investors Weigh In On Enliven Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Janus Henderson Group PLC increased its stake in Enliven Therapeutics by 74.8% in the 1st quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock worth $12,604,000 after purchasing an additional 305,397 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Enliven Therapeutics by 49.2% during the second quarter. Bank of New York Mellon Corp now owns 114,109 shares of the company’s stock valued at $2,667,000 after acquiring an additional 37,632 shares during the period. First Turn Management LLC purchased a new stake in shares of Enliven Therapeutics in the 2nd quarter valued at approximately $9,657,000. American Century Companies Inc. boosted its stake in Enliven Therapeutics by 44.7% in the 2nd quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock worth $646,000 after purchasing an additional 8,540 shares during the period. Finally, Nicholas Investment Partners LP purchased a new position in Enliven Therapeutics during the 2nd quarter worth approximately $1,310,000. 95.08% of the stock is owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.